Joint statement on Savvy Phase 3 trial in Ghana to test the effectiveness of Savvy Gel in preventing HIV

Research Triangle Park, NC and Huntingdon Valley, PA -- International efforts are underway to evaluate microbicides as a tool to prevent HIV infection in people at high risk. As part of this initiative, with funding from the U.S. Agency for International Development (USAID), Family Health International (FHI) and Cellegy Pharmaceuticals, Inc. have been working to see if a vaginal gel called Savvy is effective in preventing male-to-female transmission of HIV among women at high risk of infection in West Africa. Other organizations are conducting trials in the United States to determine if Savvy is effective as a contraceptive.

Family Health International and Cellegy Pharmaceuticals announced today that they plan to stop the HIV prevention trial of Savvy being conducted by FHI in Ghana. This decision followed a recommendation of the study's external, independent Data Monitoring Committee (DMC). The DMC reviewed the study data to date and concluded that, while there is no evidence of safety concerns based on the comparative HIV infection rates in the Savvy and placebo groups, the Ghana study would be unable to evaluate the effectiveness of the product.

The Savvy Phase 3 clinical trial in Ghana began recruitment in March 2004 and completed planned enrollment with 2,142 women in June 2005. Half of the women were given Savvy gel, and half were given a placebo gel to be inserted vaginally with pre-filled applicators. At monthly visits during each woman's year-long follow-up, each participant was tested for HIV and reported on use of the gel and any side effects or medical problems. Each participant received counseling for reducing her risk of HIV and was given condoms for use during all sexual acts. Eighteen months into the study, the observed HIV incidence in the cohort was about one-third the rate expected prior to the study.

"The reason we decided to stop the trial was that the group of women who volunteered to participate had such a low inciden

Contact: Beth Robinson
Rational PR

Page: 1 2 3

Related medicine news :

1. Joint Principles of PC-MH released by organizations representing more than 300,000 physicians
2. AHA statement recommends doctors change approach
3. CHPA statement regarding Monitoring the Future findings on cough medicine abuse
4. International AIDS Vaccine Initiative statement on male circumcision
5. AASM position statement: Treating insomnia with over-the-counter sleep aids, herbal supplements
6. American Thoracic Society publishes new statement on hepatotoxicity of antituberculosis therapy
7. NHLBI and NIH statements on totally implanted permanent artificial heart
8. ESC statement on the CHARISMA trial on Clopidogrel (Plavix)
9. ESC issues policy statement on reperfusion therapy
10. American Dietetic Association statement on new MyPyramid
11. GSK announces launch of largest ever Phase III trial in lung cancer treatment

Post Your Comments:

(Date:2/13/2019)... ... 13, 2019 , ... Intalere will hold its annual Emerging ... 2019 at the Gaylord Rockies Resort & Convention Center, Denver, Colo. The event ... improved quality of patient care, reduced costs and enhanced revenue opportunities in healthcare. ...
(Date:2/13/2019)... ... February 13, 2019 , ... Castle announced today that ... participation from existing investors Y Combinator , First Round and ... at Duo Security, René Bonvanie, CMO at Palo Alto Networks, and Olivier Pomel, CEO ...
(Date:2/13/2019)... ... 2019 , ... Dr. Jig Patel and the dental professionals at Schaumburg ... and knowledgeable dentist from St. Louis, MO, to the team. With him, ... same-day dentistry, root canals and emergency treatment. Dr. Patel, Dr. Merchant and their team ...
(Date:2/13/2019)... ... 13, 2019 , ... Surgery that moves both jaws forward – known as ... apnea (OSA), resulting in benefits that include improved breathing, daytime wakefulness and quality of ... MMA should be regarded as the preferred treatment for patients with moderate to severe ...
(Date:2/13/2019)... BEACH GARDENS, Fla. (PRWEB) , ... February 13, ... ... their exclusivity, and luxurious lifestyle publication is privileged to present Dr. David A. ... Living partnership. , Haute Beauty offers a prominent collective of leading doctors. The ...
Breaking Medicine News(10 mins):
(Date:2/16/2019)... ... February 15, 2019 , ... ControlRad, ... of radiation exposure during fluoroscopically guided procedures, is pleased to announce that ... and President of the Mobile C-arm business. , Mr. Fair has been ...
(Date:2/16/2019)... Belgium (PRWEB) , ... February 15, 2019 , ... ... and observations from multiple studies and patient registries demonstrating the value of SelectMDx ... of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place in San Francisco, ...
(Date:2/14/2019)... ... February 14, 2019 , ... ... focuses on developing and commercializing minimally-invasive, innovative spinal technologies, today announced a ... Surgical name better emphasizes our commitment to delivering new, cutting-edge, surgical solutions ...
Breaking Medicine Technology:
Cached News: